6CUX

Escherichia coli RpoB S531L mutant RNA polymerase holoenzyme in complex with Kanglemycin A

6CUX の概要

• エントリーDOI: 10.2210/pdb6cux/pdb
• 分子名称: DNA-directed RNA polymerase subunit alpha, DNA-directed RNA polymerase subunit beta, DNA-directed RNA polymerase subunit beta', ... (8 entities in total)
• 機能のキーワード: bacterial rna polymerase, kanglemycin a, transcription inhibitor, transcription, transcription-transcription inhibitor complex, transcription-antibiotic complex, transcription/antibiotic
• 由来する生物種: Escherichia coli (strain K12); 詳細
• タンパク質・核酸の鎖数: 12
• 化学式量合計: 921162.07

構造登録者

Molodtsov, V.,Murakami, K.S. (登録日: 2018-03-26, 公開日: 2018-07-25, 最終更新日: 2024-11-20)

主引用文献

Mosaei, H.,Molodtsov, V.,Kepplinger, B.,Harbottle, J.,Moon, C.W.,Jeeves, R.E.,Ceccaroni, L.,Shin, Y.,Morton-Laing, S.,Marrs, E.C.L.,Wills, C.,Clegg, W.,Yuzenkova, Y.,Perry, J.D.,Bacon, J.,Errington, J.,Allenby, N.E.E.,Hall, M.J.,Murakami, K.S.,Zenkin, N.
Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis.
Mol. Cell, 72:263-274.e5, 2018

PubMed Abstract: Antibiotic-resistant bacterial pathogens pose an urgent healthcare threat, prompting a demand for new medicines. We report the mode of action of the natural ansamycin antibiotic kanglemycin A (KglA). KglA binds bacterial RNA polymerase at the rifampicin-binding pocket but maintains potency against RNA polymerases containing rifampicin-resistant mutations. KglA has antibiotic activity against rifampicin-resistant Gram-positive bacteria and multidrug-resistant Mycobacterium tuberculosis (MDR-M. tuberculosis). The X-ray crystal structures of KglA with the Escherichia coli RNA polymerase holoenzyme and Thermus thermophilus RNA polymerase-promoter complex reveal an altered-compared with rifampicin-conformation of KglA within the rifampicin-binding pocket. Unique deoxysugar and succinate ansa bridge substituents make additional contacts with a separate, hydrophobic pocket of RNA polymerase and preclude the formation of initial dinucleotides, respectively. Previous ansa-chain modifications in the rifamycin series have proven unsuccessful. Thus, KglA represents a key starting point for the development of a new class of ansa-chain derivatized ansamycins to tackle rifampicin resistance.

PubMed: 30244835
DOI: 10.1016/j.molcel.2018.08.028

実験手法

X-RAY DIFFRACTION (4.104 Å)